Elsevier

Neuropharmacology

Volume 54, Issue 1, January 2008, Pages 235-243
Neuropharmacology

Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?

https://doi.org/10.1016/j.neuropharm.2007.06.021Get rights and content

Abstract

Cannabinoids, the active components of Cannabis sativa L. and their derivatives, inhibit tumor growth in laboratory animals by inducing apoptosis of tumor cells and inhibiting tumor angiogenesis. It has also been reported that cannabinoids inhibit tumor cell invasiveness, but the molecular targets of this cannabinoid action remain elusive. Here we evaluated the effects of cannabinoids on the expression of tissue inhibitors of metalloproteinases (TIMPs), which play critical roles in the acquisition of migrating and invasive capacities by tumor cells. Local administration of Δ9-tetrahydrocannabinol (THC), the major active ingredient of cannabis, down-regulated TIMP-1 expression in mice bearing subcutaneous gliomas, as determined by Western blot and immunofluorescence analyses. This cannabinoid-induced inhibition of TIMP-1 expression in gliomas (i) was mimicked by JWH-133, a selective CB2 cannabinoid receptor agonist that is devoid of psychoactive side effects, (ii) was abrogated by fumonisin B1, a selective inhibitor of ceramide synthesis de novo, and (iii) was also evident in two patients with recurrent glioblastoma multiforme (grade IV astrocytoma). THC also depressed TIMP-1 expression in cultures of various human glioma cell lines as well as in primary tumor cells obtained from a glioblastoma multiforme patient. This action was prevented by pharmacological blockade of ceramide biosynthesis and by knocking-down the expression of the stress protein p8. As TIMP-1 up-regulation is associated with high malignancy and negative prognosis of numerous cancers, TIMP-1 down-regulation may be a hallmark of cannabinoid-induced inhibition of glioma progression.

Introduction

Cannabinoids, the active components of Cannabis sativa L. (marijuana) and their derivatives, exert a wide array of effects by activating specific receptors that are normally engaged by a family of endogenous ligands – the endocannabinoids (Howlett et al., 2002, Piomelli, 2003). Cannabis preparations have been used in medicine for centuries, and nowadays there is a renaissance in the study of their therapeutic effects (Di Marzo and Petrocellis, 2006, Mackie, 2006). Specifically, cannabinoids have been known to exert palliative effects in cancer patients since the early 1970s. The best established of these effects is the inhibition of chemotherapy-induced nausea and vomiting, and nowadays capsules of Δ9-tetrahydrocannabinol (THC), the major active component of cannabis, and its synthetic analogue nabilone are approved for that purpose (Guzmán, 2003, Hall et al., 2005). In addition, several clinical trials are testing other potential palliative properties of cannabinoids in oncology such as appetite stimulation and pain inhibition (Guzmán, 2003, Hall et al., 2005). Besides these palliative actions, cannabinoids have been proposed as potential antitumoral agents owing to their ability to inhibit the growth and angiogenesis of various types of tumor xenografts in animal models (Guzmán, 2003). Studies on malignant brain tumors (gliomas) and other models of cancer strongly support that cannabinoids decrease tumor progression by at least two mechanisms: the apoptotic death of tumor cells (Galve-Roperh et al., 2000, Casanova et al., 2003, Carracedo et al., 2006a, Carracedo et al., 2006b) and the inhibition of tumor angiogenesis (Blázquez et al., 2003, Blázquez et al., 2004, Blázquez et al., 2006, Casanova et al., 2003, Portella et al., 2003, Pisanti et al., 2007). It has also been reported that cannabinoids inhibit the migration and spreading of tumor cells (Portella et al., 2003, Blázquez et al., 2006, Grimaldi et al., 2006). However, the molecular targets of this cannabinoid effect remain elusive. Among the various factors involved in the acquisition of migrating and invasive capacities by cancer cells, the concerted action of matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitors of metalloproteinases – TIMPs) plays a pivotal role. MMPs have been long linked to cancer cell invasion owing to their crucial involvement in extracellular matrix breakdown. Accordingly, increased expression and activation of MMPs is found in almost all human cancers compared with normal tissue, and this increase has been associated with poor patient prognosis (Egeblad and Werb, 2002, Deryugina and Quigley, 2006, Overall and Kleifeld, 2006). Likewise, cannabinoid administration down-regulates MMP-2 expression in vascular endothelial and tumor cells (Blázquez et al., 2003, Pisanti et al., 2007). In addition to the MMPs, one of the most prominent MMP inhibitors, TIMP-1, is selectively up-regulated in numerous cancers, and this has been shown to be closely associated with negative prognosis, making TIMP-1 a promising candidate for new negative-prognosis marker (Hornebeck et al., 2005, Würtz et al., 2005, Yasui et al., 2005, Chirco et al., 2006). This finding may be explained, at least in part, by MMP-independent actions of TIMP-1 such as promotion of tumor cell proliferation and survival as well as of tumor angiogenesis (Hornebeck et al., 2005, Chirco et al., 2006). This background prompted us to explore the effect of cannabinoid administration on TIMP-1 expression by cancer cells. Here we report that cannabinoid administration inhibits TIMP-1 expression in cultured glioma cells, in mice bearing gliomas and in two patients with glioblastoma multiforme. In addition, our data support that this effect is mediated by the sphingolipid ceramide and the stress protein p8, two key signaling elements of cannabinoid antitumoral action (Guzmán, 2003, Blázquez et al., 2004, Carracedo et al., 2006a, Carracedo et al., 2006b).

Section snippets

Cannabinoids

THC and JWH-133 were kindly given by Alfredo Dupetit (The Health Concept, Richelbach, Germany) and J.W. Huffman (Department of Chemistry, Clemson University, SC), respectively. For in vitro incubations cannabinoids were directly applied at a final DMSO concentration of 0.1–0.2% (v/v). For in vivo administration to mice cannabinoids were prepared at 1% (v/v) DMSO in 100 μl PBS supplemented with 5 mg/ml bovine serum albumin. No significant influence of the vehicle was observed on any of the

THC inhibits TIMP-1 expression in mouse gliomas

To test whether cannabinoid administration affects TIMP-1 levels, we generated tumors by subcutaneous inoculation of glioma cells to mice. The specificity of cannabinoid action was ascertained by the parallel study of C6.9 and C6.4 glioma cells, which constitute well established models of cannabinoid-responsive and cannabinoid-resistant cells, respectively (Galve-Roperh et al., 2000, Gómez del Pulgar et al., 2002, Carracedo et al., 2006b). Tumors were treated with either vehicle or THC and

Discussion

Despite the widely described antitumoral actions of cannabinoids in various animal models of cancer (Guzmán, 2003), the molecular effectors of these actions have not been fully characterized as yet. Here we show that cannabinoid administration down-regulates TIMP-1 expression in mice bearing gliomas as well as in two patients with recurrent glioblastoma multiforme. Cannabinoid-induced inhibition of TIMP-1 expression was also evident in cultured glioma cells, indicating that the changes observed

Acknowledgements

We are indebted to Eva Resel for expert technical assistance and to the rest of the members of the lab for discussion and advice. This work was supported by grants from Ministerio de Educación y Ciencia (SAF2006-00918 to M.G.), Comunidad de Madrid (S-SAL/0261/2006 to M.G.) and Universidad Complutense de Madrid (PR1/07-14896 to C.B.).

References (33)

  • R. Chirco et al.

    Novel functions of TIMPs in cell signalling

    Cancer Metastasis Reviews

    (2006)
  • E.I. Deryugina et al.

    Matrix metalloproteinases and tumor metastasis

    Cancer Metastasis Reviews

    (2006)
  • V. Di Marzo et al.

    Plant, synthetic, and endogenous cannabinoids in medicine

    Annual Review of Medicine

    (2006)
  • A.J. Docherty et al.

    Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity

    Nature

    (1985)
  • M. Egeblad et al.

    New functions for the matrix metalloproteinases in cancer pregression

    Nature Reviews Cancer

    (2002)
  • A.R. Folgueras et al.

    Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies

    International Journal of Developmental Biology

    (2004)
  • Cited by (41)

    • Cannabis sativa ethanolic extract demonstrated significant anti-tumor effects associated with elevated expression of AXIN1 protein in glioblastoma U87-MG cell line

      2023, Gene Reports
      Citation Excerpt :

      Additionally, an enhancement was observed in the inhibitory effects of THC on GBM cell proliferation and survival by CBD (Abrams, 2018). The findings of the pre-clinical experiments using the animal models of GBM have demonstrated that the anti-tumor activity of cannabinoids with TMZ is greater than the effect of each drug individually (Blázquez et al., 2008; López-Valero et al., 2018a; López-Valero et al., 2018b). Torres et al. (2011) have examined the in vivo and in vitro effects of combining TMZ with THC and/or CBD on GBM.

    • Cannabinoids and Breast Cancer

      2021, Discovery and Development of Anti-Breast Cancer Agents from Natural Products
    • The effects of cannabinoids on glioblastoma growth: A systematic review with meta-analysis of animal model studies

      2020, European Journal of Pharmacology
      Citation Excerpt :

      For that reason, the search for new promising compounds to treat GBM is essential. Cannabinoids, the bioactive compounds of Cannabis sativa L., exert their effects mostly by activating certain types of G-protein coupled receptors (GPCRs), which are usually triggered by a group of endogenous ligands, the endocannabinoids (Blázquez et al., 2008). The endocannabinoid system was found when studying the main bioactive compound of C. sativa, Δ9-tetrahydrocannabinol (THC) (Allister et al., 2005).

    • The protective effects of β-caryophyllene on LPS-induced primary microglia M <inf>1</inf> /M <inf>2</inf> imbalance: A mechanistic evaluation

      2019, Life Sciences
      Citation Excerpt :

      Additionally, it was showed that either CB1 or CB2 receptor activation induces apoptosis through ceramides de novo synthesis in colon cancer cells [77]. JWH-133 also showed anti-tumoral activity against gliomas through CB2 receptor and related ceramides production because of using either the CB2 antagonist or ceramides production inhibitors completely blocked the effects of JWH-133 [78]. Intriguingly, Vara et al. explained the participation of PPAR-γ receptor in the anti-tumoral activity of Δ9-tetrahydrocannabinol (THC) and JWH-015 on hepatocellular carcinoma [72].

    View all citing articles on Scopus
    View full text